This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter versus Sep 2025: revenue fell 12.6%, profit after tax fell 46.7%.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 September 2026 versus the year-ago quarter, revenue was Rs 449.66 crore versus Rs 514.27 crore, down 12.6%, and profit after tax was Rs 51.63 crore versus Rs 96.85 crore, down 46.7%. Operating margin before other income, interest, depreciation and tax narrowed to 21.7% from 30.2%. The board approved about Rs 47.1 crore for land and related costs for future capacity, funded from internal savings.
Falling revenue, profit and operating margin may pressure sentiment. The internally funded land purchase supports future capacity but commits capital.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹449.7 Cr | ₹514.3 Cr | −12.6% |
| Operating profit | ₹61.48 Cr | ₹127.6 Cr | −51.8% |
| Profit after tax | ₹51.63 Cr | ₹96.85 Cr | −46.7% |
| EBITDA margin | 21.7% | 30.3% | −8.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.